StartseiteWUXI06 • BKK
add
WuXi Biologics
Letzter Kursschluss
3,60 ฿
Preisspanne heute
3,50 ฿ - 3,56 ฿
Preisspanne im Jahr
3,16 ฿ - 4,28 ฿
Marktkapitalisierung
140,35 Mrd. HKD
Durchschnittliches Volumen
32.012,00
KGV
-
Dividendenrendite
-
Marktnachrichten
Finanzdaten
Gewinn- und Verlustrechnung (GuV)
Umsatz
Nettogewinn
| (CNY) | Dez. 2025info | Veränd. Jahresvgl. |
|---|---|---|
Umsatz | 5,92 Mrd. | 17,18 % |
Betriebskosten | 921,71 Mio. | 20,09 % |
Nettogewinn | 1,28 Mrd. | 38,35 % |
Nettoumsatzrendite | 21,70 | 18,06 % |
Gewinn je Aktie | — | — |
EBITDA | 2,28 Mrd. | 34,90 % |
Effektiver Steuersatz | 24,24 % | — |
Bilanz
Gesamtvermögen
Gesamtverbindlichkeiten
| (CNY) | Dez. 2025info | Veränd. Jahresvgl. |
|---|---|---|
Bar- und kurzfr. Invest. | 15,73 Mrd. | 46,90 % |
Gesamtvermögen | 63,70 Mrd. | 11,79 % |
Gesamtverbindlichkeiten | 10,66 Mrd. | -7,33 % |
Gesamtkapital | 53,04 Mrd. | — |
Ausgegebene Aktien | 4,13 Mrd. | — |
Kurs-Buchwert-Verhältnis | 0,31 | — |
Gesamtkapitalrentabilität | 7,70 % | — |
Kapitalrendite | 8,73 % | — |
Cashflow
Zahlungswirksame Veränderung des Finanzmittelbestands
| (CNY) | Dez. 2025info | Veränd. Jahresvgl. |
|---|---|---|
Nettogewinn | 1,28 Mrd. | 38,35 % |
Operativer Cashflow | — | — |
Barmittel aus Invest. | — | — |
Barmittel aus Finanzierung | — | — |
Zahlungswirksame Veränderung des Finanzmittelbestands | — | — |
Ungehinderter Cashflow | — | — |
Info
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
Gegründet
2010
Website
Mitarbeiter
13.252
